Target-Specific IL-2 Delivery & Activation Engineering Services
Creative Biolabs provides end-to-end rational design, engineering, and preclinical optimization of next-generation IL-2 therapeutics. Our services span customized mutein generation, advanced bioconjugation (Fc-fusion, PEGylation), TME-activated pro-drug strategies, and state-of-the-art targeting formats like bispecifics and checkpoint-gated agonists. Clients gain a validated lead molecule with a superior therapeutic index, extended half-life, and minimized systemic toxicity, accelerating their transition from discovery to advanced preclinical development.
Introduction What We Can Offer Types of Our Services Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Delivery & Activation of Target-Specific IL-2 Engineering
Interleukin-2 (IL-2) is integral to immune homeostasis, but its historical, systemic use in oncology is severely limited by toxicity (VLS) and expansion of immunosuppressive regulatory T cells, stemming from its high-affinity binding to the IL-2Rα/β/γ receptor. New engineering efforts, supported by published data, focus on designing muteins, pro-drugs, and fusion proteins that preferentially signal through the T effector cell-dominant IL-2Rβ/γ receptor, achieving the necessary balance for potent, safe anti-tumor activity by overcoming cytokine scarcity at the tumor site.
Discover how we can help - Request a consultation today to define the engineering strategy for your next lead candidate.
Fig.1 Targeting IL-2 signaling for cancer therapy. 1
What We Can Offer
Quality-by-Design (QbD) Methodology
Implementation of efficient and documented upstream and downstream process development applying QbD and process analytical techniques (PAT), ensuring a robust path to scale-up readiness.
Enhanced Mutein Stability and Yield
Strategic codon optimization to maximize protein expression efficiency, guaranteeing the stability and quality of the engineered IL-2/fusion constructs in cell banks and large-scale synthesis.
Agile Expression Optimization
Flexibility to optimize expression parameters (simulating batch, fed-batch, or continuous mode) and culture conditions to significantly maximize the yield and activity of your novel IL-2 therapeutic.
High-Standard Quality Control & Assessment
Utilization of high-standard analytical quality control tools to precisely quantify and evaluate the function, purity, and stability of the final engineered product, assuring the highest quality pre-clinical lead candidate.
Target-Specific IL-2 Delivery & Activation Engineering Services at Creative Biolabs
This service focuses on generating Immunocytokines - IL-2 muteins fused to monoclonal antibody fragments that bind highly expressed TAAs. This physically concentrates the IL-2 therapeutic at the tumor site, minimizing systemic exposure and maximizing local therapeutic index.
We design fusion proteins that specifically bind components of the extracellular matrix (ECM), highly concentrated at the tumor site. This strategy achieves cue-activated targeting, ensuring local retention and activation based on TME physiology rather than just cell surface expression.
This advanced service focuses on activating specific immune cell subsets that are vital for anti-tumor immunity. This includes our checkpoint-gated agonists or chimeric cytokine designs, which are inherently programmed to signal only through the desired intermediate-affinity receptors on CTLs and NK cells for superior Teff potency and memory T-cell maintenance.
Highlights
Engineering Mastery: Four Pillars
Creative Biolabs stands at the forefront of cytokine engineering, translating complex science into commercially viable solutions. Our commitment ensures your therapy bypasses the limitations of first-generation IL-2 through sophisticated design strategies.
Mutein Receptor Bias
Our platform advances beyond simple muteins, focusing on mutein receptor bias and PK modulation (Fc-fusion/PEGylation). We achieve targeted receptor signaling and extended systemic residence time, overcoming poor half-life and reducing off-target toxicity.
Pro-Drug Activation
We expertly utilize TME-activated pro-drug masking to ensure the IL-2 therapeutic remains inactive systemically. Activation only occurs locally within the tumor microenvironment, maximizing safety and therapeutic concentration at the disease site.
Checkpoint-Gated Agonists
Creative Biolabs actively programs the molecule for superior accumulation and selective rejuvenation of functionally exhausted T cells. This cutting-edge strategy is designed to overcome checkpoint inhibitor resistance, confirmed by published data.
Contact our team to secure these demonstrable benefits for the development of oncology assets.
Customer Reviews
-
Overcoming Checkpoint Resistance
We commissioned a checkpoint-gated agonist fusion protein to address resistance in a refractory model. The selective activation of PD-1+ TILs was precisely as predicted, a crucial finding for our combination therapy strategy. - Prof. L***a R***s.
-
Intratumoral Retention
We leveraged Creative Biolabs' site-specific PEGylation service for a high-priority asset. The resulting molecule showed clear evidence of enhanced intratumoral retention in early PK studies, eliminating the issue of rapid renal clearance we faced with the unmodified cytokine. - S***h M***n.
FAQs
Q: Is there a risk of inducing an immune response against the engineered IL-2 or the TAA target?
A: This is a genuine concern for any biologic. We address this using two strategies: 1) Site-specific PEGylation using non-natural amino acids, which has been shown to shield immunogenic epitopes, and 2) Utilizing a chimeric design that has a topologically distinct sequence, reducing the potential for cross-reactivity with endogenous human IL-2.
Q: What starting materials do you require to begin a fusion protein project?
A: We need your target antigen (TAA/TSA) sequence or antibody sequence, and the specific IL-2 backbone sequence you intend to use. If you don't have a proprietary backbone, we can assist with our proprietary Treg-sparing mutein backbones to accelerate the timeline.
Related Services
We utilize advanced technologies like site-specific bioconjugation (PEGylation) and Fc-fusion engineering to achieve prolonged systemic half-life and superior tumor retention, minimizing the need for frequent dosing.
Learn More →
A foundational service specializing in the rational design and screening of IL-2 muteins engineered to exhibit biased binding towards the high-affinity IL-2Rβ/γ receptor complex on Teff and NK cells. This maximizes Treg-sparing activity and establishes a superior therapeutic index.
Learn More →
How to Contact Us
Creative Biolabs provides an end-to-end solution that systematically solves the dual challenges of toxicity and efficacy through advanced mutein design, cutting-edge PK modulation, and sophisticated tumor-gated activation strategies. Do not let the limitations of first-generation cytokines restrict your pipeline's potential, please contact us.
Reference
-
Holcomb, Erin A, and Weiping Zou. "A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells." The Journal of clinical investigation vol. 132,3 (2022): e156628. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1172/jci156628
For Research Use Only | Not For Clinical Use
